Navellier & Associates’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.63M Hold
29,290
– – 0.14% 146
2026
Q2
$1.61M Hold
29,290
– – 0.13% 147
2026
Q1
$973K Buy
+29,290
New +$873K 0.1% 151

Other funds holding TGTX

Navellier & Associates's TGTX Position: Q3 2026 in Review

Navellier & Associates held its TG Therapeutics (TGTX) position steady in Q3 2026 at 29,290 shares worth $1.63M. The position accounts for 0.14% of the portfolio, ranked #146.

Navellier & Associates first reported a position in TGTX in Q1 2026 and has held it in 3 quarters since. 395 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

  • Navellier & Associates held 29,290 shares of TG Therapeutics worth $1.63M as of Q3 2026.
  • Navellier & Associates left its TG Therapeutics share count unchanged in Q3 2026.
  • TG Therapeutics made up 0.14% of Navellier & Associates's portfolio in Q3 2026, its #146 holding.
  • Navellier & Associates first reported a position in TG Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 395 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on Navellier & Associates's 13F filing for Q3 2026, filed 12 Nov 2026.